Pilot and Feasibility Clinical Research Grants in Diabetes, and Endocrine and Metabolic Diseases (R21)

Pilot and Feasibility Clinical Research Grants in Diabetes, and Endocrine and Metabolic Diseases (R21)

Purpose: This FOA, issued by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health, encourages pilot and feasibility clinical and behavioral studies related to the prevention or treatment of diabetes and endocrine and genetic metabolic diseases. The Pilot and Feasibility Clinical Research Grants Program is for exploratory, short-term clinical studies, so that new ideas may be investigated without stringent requirements for preliminary data. The short-term studies should focus on research questions that are likely to have high clinical impact. Studies can include testing a new prevention strategy, a new intervention or a unique combination of therapies. A high priority is the use of such studies to help stimulate the translation of promising research developments from the laboratory into clinical practice in the treatment or prevention of diabetes, endocrine diseases and genetic metabolic diseases, including cystic fibrosis.
Receipt Date: Cycle Due Dates (new submission): Feb. 16, June 16, Oct. 16
Expires: May 8, 2015
Total Awards: Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year.
Eligibility: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.
Link: http://grants.nih.gov/grants/guide/pa-files/PA-12-157.html
Print Friendly